FindTrial
Sign In

The effect of colchicine, on insulin sensitivity in individuals with type 1 diabetes and systemic low-grade inflammation (INS1GHT)

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-522528-29-00
Enrollment
26
Registered
2025-09-26
Start date
2025-12-22
Completion date
Unknown
Last updated
2025-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 diabetes

Brief summary

Change in M-value after four weeks of placebo/colchicine

Detailed description

Mean difference in M-value (adjusted to body surface area (BSA), Mean difference in M-value (adjusted to fat free mass), Mean difference in Insulin Sensitivity Index (ISI), Mean difference in average daily insulin dosage, Fold difference in Insulin sensitivity by estimated glucose disposal rate (eGDR), Fold difference in in fasting serum/plasma concentrations of inflammation markers hsCRP, IL-6, Tumour necrosis factor α

Interventions

DRUGCOLCHICINE
DRUGThe placebo tablets are visually identical to colchicine tablets and consist of Potato starch and Lactose monohydrate

Sponsors

Gentofte Hospital
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Change in M-value after four weeks of placebo/colchicine—

Secondary

MeasureTime frame
Mean difference in M-value (adjusted to body surface area (BSA), Mean difference in M-value (adjusted to fat free mass), Mean difference in Insulin Sensitivity Index (ISI), Mean difference in average daily insulin dosage, Fold difference in Insulin sensitivity by estimated glucose disposal rate (eGDR), Fold difference in in fasting serum/plasma concentrations of inflammation markers hsCRP, IL-6, Tumour necrosis factor α—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026